Table 4 Breast
Author | Cases n | Controlsa/Cohortb | Source population | Exposure definition | Exposure assessment | Drug | RR | 95% CI |
|---|---|---|---|---|---|---|---|---|
Sharpe et al. [44] | 5,882 | 23,517a | Population based | >2 tablets/week during years 2 – 5 before index date | Automated Database | NSAIDs (4%) | 0.76 | 0.63–0.92 |
Harris et al. [33] | 744 | 767a | Hospital based | >3 tablets/week during more than 5 years | Personal Interview | NSAIDs (16%) | 0.6 | 0.4–0.8 |
Harris et al. [34] | 511 | 1,534a | Hospital based | >3 tablets/week for at least 1 year | Personal Interview | Aspirin (12%) | 0.69 | 0.46–0.99 |
|  |  |  |  |  |  | NSAIDs (28%) | 0.66 | 0.52–0.83 |
Coogan et al. [25] | 6,558 | 2,925a | Hospital based | >4 days/week for >3 months. | Personal Interview | Aspirin (N.R.) | 0.7 | 0.5–0.8 |
|  |  |  |  | Continuing use during 1 year of lag time |  | NA-NSAIDs (N.R.) | 0.8 | 0.6–1.1 |
|  |  |  |  |  |  | NSAIDs (7%) | 0.7 | 0.6–0.8 |
Langman et al. [36] | 3,105 | 9,772a | Population based | >7 prescriptions during months 13–36 before index date | Automated Database | NSAIDs (6%) | 1.10 | 0.92–1.30 |
Cotterchio et al. [27] | 3,133 | 3,062a | Population based | Daily use for more than two months. 1 year before start date excluded | Mailed Questionnaire | Aspirin (14%) | 0.73 | 0.61–0.87 |
|  |  |  |  |  |  | NA-NSAIDs (11%) | 0.79 | 0.66–0.96 |
|  |  |  |  |  |  | NSAIDs (26%) | 0.76 | 0.66–0.88 |
Meier et al. [61] | 3,706 | 14,155a | Population based | ≥30 prescriptions | Automated Database | NSAIDs (8%) | 1.0 | 0.8–1.1 |
Rosenberg et al. [56] | 4,485 | 4,906a | Hospital based | >3 days/week for >3 months 1.5 years of lag timev | Personal Interview | NSAIDs (6%) | 0.8 | 0.6–1.0 |
Neugut et al. [62] | 252 | 176a | Hospital based | Chronic aspirin use | Medical Records | Aspirin (9%) | 0.80 | 0.35–1.80 |
Friedman et al. [20] | NR | 143,574b | Cohort | ever use | Medical Records | Aspirin‡ (2%) | 0.20 | 0.05–0.80 |
|  |  |  |  |  |  | NA-NSAIDs» (3%) | 0.50 | 0.28–0.88 |
Johnson et al. [58] | 938 | 27,616b | Cohort | >5 times per week | Mailed questionnaire | Aspirin (21%) | 0.71 | 0.58–0.87 |
|  |  |  |  |  |  | NA-NSAID (13%) | 1.01 | 0.83–1.25 |
Egan et al. [29] | 2,414 | 89,528b | Cohort | >2 tablets/week reported in 4 consecutive questionnaires | Mailed Questionnaire | Aspirin (15%) | 1.01 | 0.80–1.27 |
|  |  |  |  |  |  | NA-NSAIDs (4%) | 0.95 | 0.78–1.17†|
Harris et al. [35] | 393 | 32,505b | Cohort | >4 tablest/week at start date | In-hospital Questionnaire | Aspirin (13%) | 0.64 | 0.45–0.90 |
|  |  |  |  |  |  | NSAIDs (25%) | 0.57 | 0.44–0.74 |
Paganini-Hill et al. [40] | 214 | 8,881b | Cohort | Daily use of aspirin for an undefined time | Mailed Questionnaire | Aspirin (15%) | 1.05§ | 0.73–1.50 |
Thun et al. [46] | NR. | 344,350b | Cohort | More than 16 times per month for at least one year | Mailed Questionnaire | Aspirin (11%) | 0.88 | 0.62–1.24 |
Schreinemachers et al. [43] | 147 | 7,489b | Cohort | Ever use of aspirin in the 30 days prior to start date | Personal Interview | Aspirin (64%) | 0.70 | 0.50–0.96 |
-
Prevalence of exposure among controls/cohort; §Crude estimate calculated from data provided in the original manuscript; †For NA – NSAIDs only the baseline questionnaire was considered; ‡ includes only Fiorinal (aspirin, phenacetin, caffeine and butalbital combination); » indomethacin only.